All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
Chapter 7: Obstetrics, gynaecology, and urinary-tract disorders
Toggle Parent Pages
Print this page
Contraception Guidance
Management of lower urinary tract symptoms (LUTS) in men
Management of urinary incontinence in women
Management of hypertension in pregnancy
Management of nausea and vomiting in pregnancy and hyperemesis gravidarum
Guidance on prescribing for erectile dysfunction
7.1 Drugs used in obstetrics
7.2 Treatment of vaginal and vulval conditions
7.3 Contraceptives
7.4 Drugs for genito-urinary disorders
Resources for: contraception for drugs with teratogenic potential, and prescribing in pregnancy and lactation
Contact us about this page
7.1.3 Myometrial relaxants
First Line
Second Line
Specialist
Hospital Only
Atosiban
- Injection 7.5mg/ml (0.9ml 6.75mg vial)
- Concentrate of IV infusion 7.5mg/ml (5ml vial)
Terbutaline
- Injection 500 micrograms/ml
MHRA Drug Safety Update November 2013 advises that the use of short-acting β2 agonists (SABAs) for tocolysis in premature labour has been restricted to 48 hours maximum parenteral use under specialist supervision, after a European safety review. Oral SABAs should not be used in any obstetric indication.
